Eli Lilly to Acquire ORNA Therapeutics for $2.4 Billion

Edgen Stock

·Feb 09 2026, 12:37

Share to

Share to

Copy link

Key Takeaways

Eli Lilly and Company announced a major strategic acquisition, agreeing to purchase ORNA Therapeutics in a cash deal valued at up to $2.4 billion. The move is designed to bolster Lilly's drug development pipeline with advanced circular RNA (oRNA) technology.

Eli Lilly will acquire ORNA Therapeutics in a cash transaction valued at up to $2.4 billion.
The acquisition provides Lilly with access to ORNA's proprietary circular RNA (oRNA) technology, expanding its research capabilities.
This deal underscores the ongoing trend of high-value M&A within the biotechnology and pharmaceutical industries as large firms seek novel technologies.

Eli Lilly Bets $2.4 Billion on Circular RNA Technology

On February 9th, Eli Lilly and Company announced a definitive plan to acquire ORNA Therapeutics for a total potential value of $2.4 billion in cash. This acquisition gives Lilly control of ORNA's proprietary circular RNA (oRNA) technology, a novel platform for developing therapies. The deal represents a significant investment in next-generation genetic medicine, positioning Lilly to enhance its drug development pipeline with a new class of potential treatments.

Acquisition Signals Broader Pharma M&A Trend

The move is a strategic effort by Eli Lilly to secure innovative technology and fortify its long-term competitive position. By integrating ORNA's oRNA platform, Lilly aims to accelerate its research and development in several key therapeutic areas. This high-value transaction also reflects a wider consolidation trend in the pharmaceutical sector, where established giants are actively acquiring smaller, specialized biotech firms to fuel future growth and replenish their product pipelines.